Migraine And Headache
The co-presentation of headache at stroke onset in children may provide clues to underlying pathophysiologic mechanisms.
Persistent asthma was found to be associated with an increased frequency of migraine.
Migraine in pregnancy may warrant early referral to a neurologist and more intensive surveillance as a result of increased adverse birth events.
The use of combined hormonal contraceptives significantly increases the risk of ischemic stroke in women with migraine with aura but not in women with migraine without aura.
Migraine affects approximately 20% of the general population and is associated with an increased risk for ischemic stroke.
Cognitive behavioral therapy provides sustained relief from pediatric migraine with few to no adverse effects.
A follow-up study revealed the benefits of sphenopalatine ganglion stimulation for the prevention of cluster headache attacks.
Men with low serum vitamin D levels had significantly increased odds of headache compared with those who had normal levels.
While likely a placebo effect, spinal manipulation may be an option for patients with migraine refractory to treatment.
Glucocorticoids are often prescribed to RCVS patients either due to a misdiagnosis of PACNS, or fear of missing PACNS.
Cold and clammy hands and feet were common among pediatric patients with tension-type headache.
Even a single occurrence of emotional abuse during childhood predisposes an individual to migraine.
Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.
Recovery time varies depending on which class of medication the patient is overusing.
Patients with tension-type headaches had a significantly higher prevalence of anxiety and depression.
Sixty and 35% of patients achieved a 30 and 50% reduction in headache days.
Andrew Hershey, MD, PhD, FAHS, Endowed Chair and Co-Director, Cincinnati Children's Headache Center discusses the multidisciplinary approach to treating pediatric headache.
No significant difference in reduction of headache days was observed between the treatment groups and placebo.
As the treatment is currently used off-label, optimal dosing has not yet been established.
The study results suggest that headaches are a growing burden on patients and the health care system.
Eighty-one percent of patients deemed ziprasidone effective in reducing migraine severity.
Migraine sufferers had significantly higher amounts of nitrate-reducing microbes than those without migraines.
The 6 mg dose will remain available.
Acupuncture, neurostimulation, and other alternative treatments have been associated with up to a 50% reduction in headache days.
Abstinence from caffeine was independently associated with excellent acute treatment efficacy.
Two studies on the therapy were presented at the American Heart Association's Council on Hypertension 2016 Scientific Sessions.
Combined treatment approaches are more beneficial than single approaches for chronic pain conditions like migraine.
A 30% or greater decline in mean monthly moderate-to-severe headache days was met by 45.3 % (n=24) of patients treated with occipital nerve stimulation.
The drug's pediatric exclusivity expires in March 2017.
Clinicians need to remain vigilant when prescribing tramadol, as its concurrent use with opioids poses a risk of serotonin toxicity.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- In Stroke, No Clear Benefit for Head Positioning